Cervical cancer: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• TP53 2
• PD-1 19
• PD-L1 12
• PI3K 3
• AKT 1
• CTLA-4 7
• HER2 9
• CTNNB1 0
• mTOR 0
• STAT3 0
• VEGF 3
• EGFR 2
• MYC 0
• MAPK 0
• PTEN 2
• NRF2 1
• PIK3CA 3
• ERK 0
• PARP 0
• AMPK 0
• JAK 0
• TROP2 4
• YAP 0
• BRCA1 2
• GPX4 0
• HIF-1 0
• IL-6 0
• TNF 0
• FOXP3 0
• KRAS 0
• B7-H3 3
• BCL-2 0
• BRCA2 2
• HER3 1
• JNK 0
• MMP-9 0
• STING 0
• STK11 0
• AXL 0
• CD47 0
• COX-2 0
• EZH2 0
• FAK 1
• HDAC 0
• HMGB1 0
• PPAR 0
• PRAME 0
• ATM 0
• CD40 0
• CXCR4 0
• IDH 1
• LAG-3 0
• METTL3 0
• NF1 0
• NOTCH1 0
• PKM2 0
• PRMT5 0
• SHP2 0
• SIRT1 0
• ALK 0

1 of 1+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC

  Cervical Cancers Escaping HPV Screening: Decoding HPV-Independent Carcinogenesis through Multi-Omics Profiling (ESCAPE-HPV)

  Karolinska Institutet· Stockholm, Sweden· EU contribution €1,493,450· until Dec 2031

• European Commission (Horizon Europe) · HORIZON-RIA

  Offering combined HPV vaccination and HPV test-based cervical screening to vulnerable populations. A hybrid efficacy and implementation study. (HPV-FASTER-Implement)

  Institut National de la Sante Et de la Recherche Medicale· Paris, France· EU contribution €6,602,445· until Dec 2029· 8 countries

• European Commission (Horizon Europe) · HORIZON-JU-RIA

  Understanding vaccination hesitancy and evaluating single dose and gender-neutral vaccination for improving uptake of HPV vaccines in West and East Africa. (IMPROVE-HPV)

  Institut Catala D'oncologia· Hospitalet de Llobregat, Spain· EU contribution €3,613,288· until May 2028· 4 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Engineering B cells to fight cancer (EngineerBcells)

  Tel Aviv University· Tel Aviv, Israel· EU contribution €1,996,250· until Sept 2027

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  Dual screening by Spectral Artificial Visual Examination (SAVE) for Female Genital Schistosomiasis (FGS) and cervical cancer. Digital, new, low-cost, and simple screening and training. (DUALSAVE-FGS)

  Oslo Universitetssykehus Hf· Oslo, Norway· EU contribution €7,984,441· until Aug 2027· 6 countries

5 of 6 running projects, newest first. Listed amounts together: €23.2m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 28
• Organoids 10
• Mendelian Randomization Analysis 13
• CRISPR-Cas Systems 21
• Gene Expression Profiling 70
• Sequence Analysis, RNA 5
• Whole Genome Sequencing 1
• Exome Sequencing 3
• Proteomics 18
• Metabolomics 9
• Mass Spectrometry 4
• Flow Cytometry 25
• Immunohistochemistry 46
• Liquid Biopsy 8
• Circulating Tumor DNA 6
• Xenograft Model Antitumor Assays 66
• Positron-Emission Tomography 14
• Magnetic Resonance Imaging 92
• Machine Learning 63
• Deep Learning 50
• Cohort Studies 82
• Genome-Wide Association Study 14

• Compliance to National Cancer Grid of India Guidelines for Locally Advanced Cervical Cancer: Results From a Multicentric Observational Cohort in India.

  JCO Glob Oncol, Nov 2026

• Prevalence and Predictors of Abnormal Cervical Cytology Among Women Living With HIV and Without HIV From the MACS/WIHS Combined Cohort Study.

  J Acquir Immune Defic Syndr, Nov 2026

• Hypofractionated 44 Gy in 20 fractions versus conventional chemoradiation in cervical cancer: 2-year results of the randomized HYPOCx-iRex trial with an exploratory pooled analysis of a single-institute EMBRACE-II cohort.

  Brachytherapy, Oct 2026

• Age-specific and menopause-specific associations between BMI change and the risk of cervical and ovarian cancers: a population-based cohort study.

  Menopause, Oct 2026

• Long-term risk of cancer following cervical intraepithelial neoplasia: A significant study leveraging Taiwan's national health insurance research database.

  Taiwan J Obstet Gynecol, Sept 2026

• Outcomes and patterns of management of metastatic/recurrent cervical carcinoma in Malaysia: A single institutional observational cohort study.

  Med J Malaysia, Sept 2026

• Frequent detection of high-risk HPV types other than HPV 16/18 in a cohort of French women who claimed to have been vaccinated.

  Arch Virol, Aug 2026

• Large-cohort screening projects in seven regions of China demonstrate the efficacy of extended HPV genotyping in triaging HPV-positive women.

  Int J Infect Dis, Aug 2026

• Early post-operative complications after fertility-sparing surgery for cervical carcinoma: a retrospective study of a centralized national cohort of 127 consecutive women.

  Int J Gynecol Cancer, Aug 2026

• PAX1 and ZNF582 Methylation as a Triage Strategy in Cytologic and hrHPV+ Scrapings in Both Chinese and Dutch Cohorts.

  Cancer Epidemiol Biomarkers Prev, Aug 2026

See which targets of this disease your abstract mentions, and go to the people working on them.